The Annual International PfSPZ Consortium Met in Toronto, Canada

The Annual International PfSPZ Consortium Met in Toronto, Canada on November 8th & 9th, 2025

December 10, 2025 By In News No Comments
The 2025 iPfSPZ-C meeting brought together scientists from around the world to review an extraordinary year of progress in Plasmodium falciparum sporozoite (PfSPZ) vaccine and other SPZ research. Over a day and a half, 48 scientists from 11 countries presented major scientific breakthroughs, steady advances in product development, and coordinated plans for global evaluation of Sanaria’s PfSPZ-based malaria vaccines to the in-person participants and on-line participants around the world.
Read More

A Single-Dose Breakthrough: PfSPZ-LARC Vaccines Offer Transformative Protection Against Malaria

February 12, 2025 By In News, Press Releases No Comments
Scientists at Sanaria and Seattle Children’s Research Institute’s Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking malaria vaccine, Sanaria® PfSPZ-LARC2 Vaccine, designed to provide high-level protection with just one dose. This innovative approach leverages decades of research and cutting-edge genetic engineering to combat one of the world’s deadliest diseases.
Read More

Indonesian collaborators and stake holders attend meeting in Jakarta to report successful results of trial of PfSPZ vaccines in Indonesian soldiers.

July 24, 2024 By In In The Media, News No Comments
Overview: In 2022-2023, Sanaria® PfSPZ Vaccine and Sanaria® PfSPZ-CVac (CQ) malaria vaccines were assessed in a phase 2 clinical trial in Papua, Indonesia, against genetically diverse, naturally transmitted Plasmodium falciparum in malaria naïve, Indonesian military personnel.  On July 17, 2024, the Faculty of Medicine, University of Indonesia (FMUI) hosted a scientific meeting in Jakarta, Indonesia attended by representatives of all the stakeholders to review the trial.
Read More

Employees of the Month: Amparo Tellez and Marcus Prince

April 16, 2024 By In Employee of the Month No Comments
The Sanaria employees of the month for March 2024 are Amparo Tellez and Marcus Prince. Amparo and Marus are members of the Manufacturing team and were nominated for employees of the month for their professionalism, consistency, and flexibility – which is key to prepare and maintain a clean and aseptic manufacturing environment that allows Sanaria operations to meet all regulatory standards.
Read More

Novel vaccine, PfSPZ-LARC2 Vaccine, to prevent malaria infection developed by Seattle Children’s Research Institute and Sanaria ready for human testing

April 1, 2024 By In In The Media, News, Press Releases No Comments
In a report published on March 21, 2024 in EMBO Molecular Medicine (A replication competent Plasmodium falciparum parasite completely attenuated by dual gene deletion) investigators at Seattle Children’s Research Institute and Sanaria Inc. describe the development of a whole malaria parasite vaccine strain that infects the liver, develops to the late liver stage, and then gets completely stuck and cannot burst out of the liver to cause symptomatic blood infection.
Read More

News Categories

About Sanaria

Sanaria is a Maryland-based biotechnology company developing innovative vaccines that protect against malaria. We are focused on African children, the population most urgently in need of protection.

Latest News

Behind the Scenes: Vaccine Manufacturing

Contact Us

We welcome your feedback and inquiries. Please be in touch.

Address:

Sanaria Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850

Phone:

+1.301.770.3222

Email:

sanaria@sanaria.com

Social: